9 completed, 6 terminated, 1 active not recruiting, 1 unknown. 10 Phase 2, 3 Phase 3, 3 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Terminated 4, Unknown 1 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Phase 4 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Zilretta: new trials by email Literature Review of Zilretta trials Research Report on Zilretta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip Zilretta, Triamcinolone Acetonide - Osteoarthritis of Hip | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 1 | 2025-07-25 | 2025-12-22 |
| ZILRETTA in Subjects With Shoulder Osteoarthritis ZILRETTA, Placebo - Glenohumeral Osteoarthritis | Phase 3 | Active not recruiting | Pacira Pharmaceuticals, Inc | 150 | 2024-02-05 | 2026-05-29 |
| Trial Comparing Three Single Dose Injections for Knee Osteoarthritis Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe - Osteoarthritis, Knee | Phase 4 | Terminated | Ohio State University | 6 | 2022-08-02 | 2026-09-17 |
| Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis Resiniferatoxin, Zilretta, Placebo - Osteoarthritis, Knee, Knee Osteoarthritis | Phase 2 | Unknown | Sorrento Therapeutics, Inc. | 124 | 2021-11-15 | 2023-01-17 |
| Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension - Osteoarthritis, Knee | Phase 4 | Completed | ROC Foundation | 20 | 2020-11-30 | 2021-09-27 |
| Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury Zilretta, Placebo - Tibial Meniscus Injuries, Tibial Meniscus Tears | Phase 2 | Terminated | Austin V Stone | 1 | 2020-08-21 | 2023-07-27 |
| Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis FX006, Normal Saline - Osteoarthritis of the Shoulder, Adhesive Capsulitis | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 19 | 2019-11-07 | 2024-01-24 |
| ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis triamcinolone acetonide extended-release injectable suspension - Adhesive Capsulitis, Frozen Shoulder | Phase 1 | Terminated | University of Virginia | 39 | 2019-06-21 | 2025-05-13 |
| Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee FX006 32 mg - Osteoarthritis, Knee | Phase 3 | Completed | Pacira Pharmaceuticals, Inc | 129 | 2018-04-24 | 2024-01-24 |
| The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA Zilretta - Knee Osteoarthritis | Phase 4 | Completed | University of Kansas Medical Center | 70 | 2018-03-19 | 2022-05-05 |
| Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip FX006 32 mg, TAcs 40 mg - Osteoarthritis of the Shoulder, Osteoarthritis of the Hip | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 55 | 2017-12-18 | 2024-01-24 |
| Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA FX006 32 mg, TAcs 40 mg - Bilateral Knee Osteoarthritis | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 24 | 2017-12-06 | 2024-01-24 |
| Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes FX006 32 mg, TCA IR 40 mg - Osteoarthritis of the Knee, Type 2 Diabetes Mellitus | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 33 | 2016-04-01 | 2024-01-24 |
| Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee FX006 32 mg, TCA IR 40 - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 81 | 2015-11-01 | 2024-01-24 |
| Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee FX006 32 mg, TCA IR 40 mg - Post-traumatic Osteoarthritis of the Knee | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 6 | 2015-02-01 | 2024-01-24 |
| Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee FX006, Placebo, TCA IR 40 - Osteoarthritis of the Knee | Phase 3 | Completed | Pacira Pharmaceuticals, Inc | 486 | 2015-01-01 | 2024-01-24 |
| Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee FX006 32 mg, Placebo, FX006 16 mg - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 310 | 2014-04-01 | 2024-01-24 |
Osteoarthritis (10) · Osteoarthritis, Knee (9) · Pain (9) · Bursitis (2) · Osteoarthritis, Hip (2) · Anterior Cruciate Ligament Injuries (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Tibial Meniscus Injuries (1)
Pacira Pharmaceuticals, Inc (11) · Austin V Stone (1) · Ohio State University (1) · ROC Foundation (1) · Sorrento Therapeutics, Inc. (1) · University of Kansas Medical Center (1) · University of Virginia (1)
United States (17) · Canada (2) · Australia (1) · Denmark (1) · Estonia (1) · Hong Kong (1) · Lithuania (1) · Romania (1) · United Kingdom (1)
Neil Bodick, MD (5) · Scott Kelley, MD (4) · Austin Stone, MD, PhD (1) · Brian Werner, MD (1) · Martin Ferrillo (1) · Michael Baria (1) · Mike Royal, MD (1) · Neil A Segal, MD (1) · Nino Joy (1) · Nino Joy, MD (1) · Sara C DePaoli (1) · Timothy J Bray, MD (1)
PMID 29088579, PMID 30203101, PMID 30968336, PMID 31662801, PMID 34350546, PMID 34791634, PMID 35258839